Kristen Ambrose, who serves as Senior Vice President and Chief Accounting Officer at Vertex Pharmaceuticals (NASDAQ: VRTX), disclosed a sale of 223 shares of common stock on February 25, 2026 at a price of $486.35 per share, for a total transaction value of $108,456.
The transaction was reported on a Form 4 filed with the U.S. Securities and Exchange Commission and was carried out under a company-approved 10b5-1 trading plan that was put in place on August 8, 2025. The filing also shows that on February 24, 2026 Ambrose sold 546 shares at $485.11 per share, for proceeds of $264,870.
After completing these dispositions, Ambrose's direct holdings in Vertex amount to 6,981 shares. At the time of reporting, Vertex's common stock was trading at $480.13, which corresponds to a market capitalization of $121.97 billion.
Independent analysis from InvestingPro cited in the filing indicates the stock appears overvalued relative to its Fair Value and notes Vertex may be listed on the Most Overvalued list. The same source assigns Vertex a "GREAT" financial health score and highlights a 23.4% total return for the stock over the past six months. The company is shown to trade at a price-to-earnings ratio of 31.29 and is identified as a significant participant in the Biotechnology sector.
On the corporate results front, Vertex reported fourth-quarter 2025 revenue of $3.19 billion, which exceeded analyst expectations of $3.18 billion. Earnings per share for that quarter were $5.03, slightly under analyst forecasts of $5.08.
Analyst coverage referenced in the filing indicates continued optimism from some research houses. Cantor Fitzgerald raised its price target for Vertex to $590, pointing to the potential for the company's renal franchise to reach a scale comparable to its cystic fibrosis business, which the filing notes generates over $12 billion annually. Separately, Oppenheimer upgraded Vertex to Outperform and set a price target of $540, citing developments in the company's renal pipeline candidates, povetacicept and inaxaplin.
These corporate results and analyst moves provide context for the insider sale but do not, by themselves, indicate a change in company strategy or outlook. The Form 4 disclosure confirms the mechanics of the trades and the insider's remaining stake, while public metrics and analyst commentary paint a mixed picture of valuation and growth potential.
Key figures:
- Insider sale on Feb 25, 2026: 223 shares at $486.35 - $108,456
- Insider sale on Feb 24, 2026: 546 shares at $485.11 - $264,870
- Post-sale insider ownership: 6,981 shares
- Current share price cited: $480.13; Market cap: $121.97 billion
- Q4 2025 revenue: $3.19 billion; Q4 2025 EPS: $5.03